Stock vs Stock Comparison

Catalyst Pharmaceuticals, Inc. vs Abbott Laboratories

CPRX wins the Tale of the Tape 5–3.

CPRX
ABT$86.99

🏆 Tale of the Tape

53
CPRXABT
36.4%Profitability (Net Margin)14.7%
18.0xValuation (P/E)24.0x
21.3%Efficiency (ROIC)10.1%
5/9Health (Piotroski F)5/9
Safety (Altman Z)4.9
19.8%Growth (Rev YoY)5.7%
Risk (Sharpe 1Y)-1.05
0.16xBalance Sheet (D/E)0.64x
FCF Yield4.21%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Fundamentals

MetricCPRXABT
Market Cap$3.8B$149.1B
P/E Ratio18.0x24.0x
Forward P/E10.0x14.1x
P/B3.77x2.86x
Dividend Yield2.94%
Beta0.720.65

Quantitative Metrics

MetricCPRXABT
DCF Fair Value$65.94$57.20
DCF Upside-43.2%
Piotroski F5/95/9
Altman Z4.87
Beneish M-1.78-2.53
FCF Yield4.21%
Net Debt/EBITDA-2.4x0.1x
ROIC21.3%10.1%
WACC9.4%
ROIC – WACC0.7pp
Gross Margin85.2%56.4%
Net Margin36.4%14.7%
Rev Growth YoY19.8%5.7%
Sharpe (1Y)-1.05
Max Drawdown 3Y
FCF Payout Ratio56%

CPRX Price

Loading chart...

ABT Price

Loading chart...

ETF Exposure

CPRX found in:

XBI0.97%
SLYG0.43%
SPSM0.22%
VTWO0.10%
VFQY0.08%
VHT0.05%
SPTM0.00%

ABT found in:

IHI16.06%
IYH2.88%
XLV2.85%
VHT2.55%
DGRW1.71%
XHE1.36%
NOBL1.34%
SDY0.99%
MGV0.78%
VIG0.71%
VFMV0.69%
SCHV0.68%
VYM0.65%
VTV0.61%
IWD0.58%
QUS0.57%
SPYV0.53%
VONV0.48%
IVV0.37%
SPLG0.37%
ESGV0.36%
ITOT0.33%
SCHX0.33%
SCHB0.30%
VOO0.26%
VONE0.24%
SPY0.24%
URTH0.24%
VTI0.23%
SPTM0.22%
ACWI0.20%
RSP0.17%
VT0.14%
ONEO0.08%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

CPRX vs ABT: Head-to-Head Analysis

Catalyst Pharmaceuticals, Inc. (CPRX) and Abbott Laboratories (ABT) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, CPRX leads 5–3 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, CPRX generates a return on invested capital (ROIC) of 21.3% compared to ABT's 10.1%. This suggests CPRX is more effective at deploying capital to generate shareholder returns.

CPRX appears in 7 ETFs tracked by SecuritiesDB, while ABT appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, CPRX or ABT?

Our quantitative analysis compares CPRX and ABT across nine fundamental dimensions. CPRX wins the Tale of the Tape 5–3. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are CPRX and ABT correlated?

Correlation data is not yet available for this pair. Check back after both stocks have sufficient trading history.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.